Presented by cshlpress…

American Diabetes Association (ADA) Roundup

• The big news of the day was from ADA. A pivotal, long-awaited study revealed that cardiac bypass surgery, angioplasty and stents were no better than standard drugs for treating patients with stable heart disease — even in patients with diabetes. [ABC News]

• Doctors are questioning the latest Avandia study. [WSJ]

• Arena Pharmaceuticals was a big winner at ADA today. [Yahoo!Finance]

• So was Tolerx. [PRNewswire]

• XOMA has some preclinical data with its IL-1 inhibitor. [Yahoo!Finance]

• Biodel provided more info on its VIAject (ultra-rapid-acting injectable human insulin) technology. [Yahoo!Finance]

Other Stuff

• Lundbeck’s LuAA21004 fails a late stage depression study – shares tank. [FierceBiotech]

• Novartis’ Afinitor® (everolimus) shrinks tumors by more than 50% in one third of patients with lymphoma. [Reuters]

• Cubist Pharmaceuticals’ and Alnylam’s inhaled RNAi drug safe in lung transplant patients. [Bloomberg]

• Progenics Pharmaceuticals slimming down even further. [FierceBiotech]

• Pfizer’s Kindler makes Goldman some cash in Wyeth deal. [Bloomberg]

• Finally, Merck’s heart failure drug, MK-7418 (rolofylline) failed a Phase 3 study last week after it failed to meet its primary or secondary efficacy endpoints. [PharmaTimes]

Anonymous Tip? Comments? Contact us: hr AT iguanabio DOT com

Related Posts